Abstract: Provided herein are compositions comprising anti-HLA-Ib antibodies (monoclonal, mixed monoclonal, recombinant, chimeric, humanized or human antibodies) as IVIg mimetics and methods for using the same for the prevention, treatment, therapy and/or amelioration of inflammation induced diseases and allograft rejection. In certain embodiments, the anti-HLA-Ib antibodies strongly mimic IVIg in immunoreactivity to HLA class Ia (HLA-A, HLA-B and HLA-Cw) and Ib antigens (HLA-E, HLA-F and HLA-G). In certain embodiments, the anti-HLA-Ib antibodies strongly mimic IVIg in immunomodulatory or immunosuppressive activities. Methods are also provided herein to induce production of polyclonal anti-HLA-Ib antibodies in cancer patients for restoring anti-tumor activities of CD8+ T cells and NK cells, by active specific immunotherapy.
Type:
Grant
Filed:
January 10, 2013
Date of Patent:
October 13, 2020
Inventors:
Mepur H. Ravindranath, Paul I. Terasaki
Abstract: Materials and methods for identifying and using MEW molecule variants for activating self-reactive T cells in a peptide-specific manner, and their use to focus autoimmune cellular responses against diseases such as cancers and persisting viral infections, are described.
Type:
Grant
Filed:
April 22, 2016
Date of Patent:
October 6, 2020
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: The present disclosure provides, in part, compositions comprising peptides that immunospecifically bind to a defined binding partner, such as MHC class I polypeptide-related sequence A (MICA), or an epitope thereon. In some embodiments, the peptides comprise one or more complementarity determining regions relating to the complementarity regions shown in Table 1. The disclosure also provides methods of treating cancer in a subject using the compositions disclosed herein, and methods of isolating human antibodies from cancer patients following immunotherapy.
Type:
Grant
Filed:
July 15, 2016
Date of Patent:
October 6, 2020
Assignee:
Dana-Farber Cancer Institute, Inc.
Inventors:
Kai W. Wucherpfennig, Bettina Franz, Kenneth F. May, Jr., Glenn Dranoff, F. Stephen Hodi, Christopher Harvey
Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
Type:
Grant
Filed:
April 6, 2017
Date of Patent:
September 8, 2020
Assignees:
INSTITUT PASTEUR, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
Abstract: The invention provides compositions and methods of culturing Natural Killer Cells that increase viability, proliferation and cytotoxicity following cryopreservation.
Abstract: The present disclosure provides, in part, compositions comprising peptides immuno specifically binds to defined binding partners, wherein the peptides comprise at least complementarity determining regions relating to the complementarity regions shown in Table 1.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
August 18, 2020
Assignee:
DANA-FARBER CANCER INSTITUTE, INC.
Inventors:
Kai W. Wucherpfennig, Glenn Dranoff, F. Stephen Hodi, Bettina Franz, Kenneth F. May, Jr., Christopher Harvey
Abstract: Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from CDCA1 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the CDCA1 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e.
Abstract: The present invention relates to a method for activating helper T cells, which includes the step of activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the WT1 peptide has the ability to bind to any MHC class II molecule of an HLA-DRB1*0101 molecule, an HLA-DRB1*0401 molecule, an HLA-DRB1*0403 molecule, an HLA-DRB1*0406 molecule, an HLA-DRB1*0803 molecule, an HLA-DRB1*0901 molecule, an HLA-DRB1*1101 molecule, an HLA-DRB3*0202 molecule, an HLA-DRB4*0101 molecule, an HLA-DPB1*0201 molecule or an HLA-DPB1*0301 molecule, and the like.
Type:
Grant
Filed:
October 4, 2011
Date of Patent:
May 19, 2020
Assignees:
International Institute of Cancer Immunology, Inc., OTSUKA PHARMACEUTICAL CO., LTD.
Abstract: Provided herein are compositions comprising purified antibodies and fragments thereof that are specifically immunoreactive to only human leukocyte antigen E (HLA-E) but not to other HLA Ia and HLA-Ib alleles. Also provided are methods of their making and diagnostic and therapeutic applications. The monospecific HLA-E antibodies are highly specific and can be used for diagnosing or localizing the presence of HLA-E on normal or diseased cells or tissues. The monospecific HLA-E antibodies can also be used for cancer therapies, likely through regulation of the CD94/NKG2a on Cytotoxic and/or Natural Killer T cells.
Type:
Grant
Filed:
July 5, 2012
Date of Patent:
May 19, 2020
Inventors:
Mepur H. Ravindranath, Paul I. Terasaki
Abstract: The present invention relates to MHC-peptide complexes and uses thereof in the diagnosis of, treatment of or vaccination against a disease in an individual. More specifically the invention discloses MHC complexes comprising Mycobacterium tuberculosis antigenic peptides and uses there of.
Type:
Grant
Filed:
September 29, 2008
Date of Patent:
April 7, 2020
Assignee:
Agilent Technologies, Inc.
Inventors:
Jørgen Schøller, Liselotte Brix, Henrik Pedersen, Tina Jakobsen
Abstract: The invention relates a compound comprising (a) a peptide and (b) a carrier, wherein said peptide having at least the motif X-X-X-X-X-X-X, wherein at least one amino acid residue X is glycosylated, said peptide being linked to the peptide binding protein and said carrier comprises at least a MHC binding motif being linked to said peptide as well as pharmaceutical compositions comprising said compound and the use of said compound or pharmaceutical composition for the treatment of a disease, such as an inflammatory joint disease. The subject matter of the application is exemplified with peptides derived from type II collagen such as peptides having at least the sequence AGFKGEA, or IAGFKGEQPKG, or the peptide AAAKAAA. Preferably a hydroxylysine in the peptides are glycosylated.
Type:
Grant
Filed:
March 16, 2015
Date of Patent:
March 17, 2020
Inventors:
Rikard Holmdahl, Jan Kihlberg, Balik Dzhambazov, Mikael Vestberg
Abstract: The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.
Type:
Grant
Filed:
February 7, 2013
Date of Patent:
March 3, 2020
Assignee:
Innate Pharma, S.A.
Inventors:
Mathieu Blery, Laurent Gauthier, Ivan Perrot, Cecile Bonnafous
Abstract: The present invention provides HLA-DR (MHC class II) binding peptides derived from the ovarian/breast cancer associated antigens, Human Epidermal Growth Factor Receptor 2 (HER-2/neu), Carcinoembryonic Antigen (CEA), Insulin Growth Factor Binding Protein 2 (IGFBP-2), and Cyclin D1. The immunogenic peptides can be used in cancer vaccines.
Type:
Grant
Filed:
December 16, 2016
Date of Patent:
February 11, 2020
Assignees:
Mayo Foundation for Medical Education and Research, University of Washington
Inventors:
Keith L. Knutson, Mary L. Disis, John D. Fikes, Melanie Beebe, Glenn Ishioka
Abstract: The present invention relates to a method for the absolute quantification of naturally processed HLA-restricted cancer peptides, i.e. the determination of the copy number of peptide(s) as presented per cell. The present invention can not only be used for the development of antibody therapies or peptide vaccines, but is also highly valuable for a molecularly defined immuno-monitoring, and useful in the processes of identifying of new peptide antigens for immunotherapeutic strategies, such as respective vaccines, antibody-based therapies or adoptive T-cell transfer approaches in cancer, infectious and/or autoimmune diseases.
Abstract: This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of TR1 cells and/or B cells in an antigen-specific manner and treating diseases and disorders in a subject in need thereof.
Abstract: Embodiments herein report compositions of and methods for making and using alpha-1 antitrypsin (AAT) fusion molecules or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating an AAT fusion molecule of use in pharmaceutically acceptable compositions to treat a subject in need of AAT therapy or treatment. In other embodiments, compositions and methods disclosed herein concern linking AAT or derivative thereof to an immune fragment.
Type:
Grant
Filed:
January 10, 2013
Date of Patent:
November 19, 2019
Assignees:
The Regents of the University of Colorado, A Body Corporate, Konkuk University Industry Cooperation Foundation
Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
Type:
Grant
Filed:
June 28, 2013
Date of Patent:
October 8, 2019
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Hans-Georg Rammensee, Stefan Stevanovic, Cecile Gouttefangeas, Toni Weinschenk, Peter Lewandrowski
Abstract: The present application discloses proteins or peptides and methods of using such proteins or peptides to evaluate the immune status of a patient. In one embodiment, proteins or peptides may be used to detect endogenous calnexin specific CD4 T cells. In one preferred embodiment, the proteins or peptides may comprise peptide-MHCII tetramers (pMHC tetramers).
Abstract: A method for producing an examination reagent includes adding a helper ligand to an unfolded receptor protein in an initial solution so as to provide a pre-solution of the examination reagent with a folded receptor protein. The folded receptor protein comprises a bonded helper ligand which can be exchanged with an examination peptide.
Type:
Grant
Filed:
January 3, 2013
Date of Patent:
August 20, 2019
Assignee:
JACOBS UNIVERSITY BREMEN GGMBH
Inventors:
Sebastian Hartmut Springer, Sunil Kumar Saini